BOB customers can now use RuPay Credit Cards on UPI
BoB Credit Card customers can now use their RuPay Credit Cards on UPI with BHIM and other UPI-enabled Apps, BOB Financial Solutions Ltd (BFSL) said on Wednesday.
BOB customers can now use RuPay Credit Cards on UPI
New Delhi: BoB Credit Card customers can now use their RuPay Credit Cards on UPI with BHIM and other UPI-enabled Apps, BOB Financial Solutions Ltd (BFSL) said on Wednesday. BFSL is a wholly owned subsidiary of Bank of Baroda, and National Payments Corporation of India (NPCI). This enablement would open doors for Bank of Baroda RuPay Credit Card users to transact across all the merchant outlets with QR codes and POS devices in the country backed by convenience and security assurance of UPI, a joint statement said. Credit Card on UPI gives our customers access to the ease and convenience of transacting on UPI while they continue to enjoy the benefits of a credit card, BoB managing director Sanjiv Chadha said.
Renault India hits 9 lakh sales mark
New Delhi: French auto major Renault on Wednesday said it has crossed the 9 lakh units milestone in cumulative sales in India in the last 11 years. The company, which started selling its made-in-India vehicles from 2012, currently sells entry level car Kwid, compact SUV Kiger and multipurpose vehicle Triber. "India is a strategic and among the top five markets for Groupe Renault and we have a clear long-term strategy in mind for the country. We have formulated a strong product-offensive plan for India, with heavy emphasis on localisation in future range of products," Mamillapalle said over the last few years, Renault has established a strong foundation in India.
Mankind Pharma Q4 PAT up 52%
New Delhi: Mankind Pharma on Wednesday reported 52 per cent increase in consolidated profit after tax (PAT) at Rs 294 crore for March quarter 2022-23, aided by robust sales. The company had logged a PAT of Rs 193 crore in January-March 2021-22. Revenue from operations rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period, Mankind Pharma said in a statement. In 2022-23, the PAT declined 10 per cent to Rs 1,310 crore from Rs 1,453 crore in the previous year.
